Is­rael's VBL Ther­a­peu­tics hit with CMC de­lays in ovar­i­an can­cer study; No­vo Hold­ings buys out di­ag­nos­tics play­er BBI

VBL Ther­a­peu­tics has hit a road­block in its Phase III study for plat­inum-re­sis­tant ovar­i­an can­cer.

Batch­es of the VB-111 com­pound be­ing eval­u­at­ed in the study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER